Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single Group, Multi-center, Repeat-dose Long-term Extension Study to Evaluate the Long-term Safety and Efficacy of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

NCT05321979 is registered in ClinicalTrials.gov with Medytox Korea as lead sponsor.

NCT NCT05321979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single Group, Multi-center, Repeat-dose Long-term Extension Study to Evaluate the Long-term Safety and Efficacy of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
Lead sponsor
Medytox Korea
Phase
Phase 3
Overall status
Completed
Start date
February 7, 2022
Completion date
May 30, 2023
Enrollment
253 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar frown lines